Rakuten Securities Inc. Makes New Investment in Bristol-Myers Squibb (NYSE:BMY)

Rakuten Securities Inc. bought a new position in shares of Bristol-Myers Squibb (NYSE:BMY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 857 shares of the biopharmaceutical company’s stock, valued at approximately $44,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMY. True Wealth Design LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $26,000. Coppell Advisory Solutions Corp. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $31,000. Coppell Advisory Solutions LLC acquired a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at approximately $28,000. Live Oak Investment Partners acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $33,000. Finally, OFI Invest Asset Management acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at approximately $25,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 1.0 %

BMY opened at $48.30 on Friday. Bristol-Myers Squibb has a 1-year low of $47.58 and a 1-year high of $70.93. The stock’s fifty day simple moving average is $51.25 and its 200 day simple moving average is $51.57. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The stock has a market cap of $97.89 billion, a PE ratio of 12.51, a price-to-earnings-growth ratio of 1.49 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. During the same quarter in the prior year, the business earned $1.82 EPS. The firm’s revenue for the quarter was up .6% on a year-over-year basis. As a group, research analysts expect that Bristol-Myers Squibb will post 6.47 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.97%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is 62.18%.

Analysts Set New Price Targets

Several brokerages recently issued reports on BMY. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, Bank of America cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $61.18.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.